Mark Bell

Mark Bell has a diverse work experience in the biopharmaceutical industry. Mark has worked as a Principal Bioprocessing Scientist at Purespring Therapeutics since October 2021. Previously, Mark held the role of Subject Matter Expert Vector Production at The Janssen Pharmaceutical Companies of Johnson & Johnson from February 2021 to October 2021.

Prior to these positions, Mark worked at Cell and Gene Therapy Catapult from March 2015 to February 2021. Mark first served as a Manufacturing Development Scientist, where they were involved in various tasks related to gene therapy drug production. Later, they became a Senior Industrialisation Scientist, focusing on process industrialization.

In the earlier stages of their career, Mark worked at Oxford BioMedica as a Biotechnologist from June 2013 to March 2015. Here, they gained experience in manufacturing gene therapy drugs using Lentiviral vectors in a cGMP facility.

Before that, Mark worked at Oxford Immunotec as a Production Scientist from October 2011 to June 2013. In this role, they were responsible for formulating and dispensing approved peptides in a sterile environment, adhering to Good Manufacturing Practice.

Overall, Mark Bell has extensive experience in bioprocessing, vector production, industrialization, and manufacturing of gene therapy drugs in the biopharmaceutical industry.

Mark Bell attended the University of Strathclyde from 2009 to 2011, where they obtained a Bachelor of Science (BSc) degree in Microbiology and Immunology.